USA flag logo/image

An Official Website of the United States Government

The in vitro hepatitis C virus infection system as a drug discovery tool

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
85316
Program Year/Program:
2007 / SBIR
Agency Tracking Number:
AI074101
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
APATH, LLC
APATH, LLC 893 N. WARSON RD. SAINT LOUIS, MO 63141
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2007
Title: The in vitro hepatitis C virus infection system as a drug discovery tool
Agency: HHS
Contract: 1R43AI074101-01
Award Amount: $100,713.00
 

Abstract:

DESCRIPTION (provided by applicant): Hepatitis C virus (HCV) infection is a major cause of liver disease throughout the world. Existing therapies are suboptimal and the search for alternative therapies is imperative. Recent years have seen a tremendous inc rease in efforts to identify more effective therapies against HCV. These efforts have been greatly facilitated by sub-genomic HCV replicon systems that efficiently replicate in cell culture. However, despite all the benefits of these replicon systems, the lack of an infectious HCV system in cell culture is still an impediment to all aspects of HCV studies, particularly the development of HCV anti-viral therapies. The recent development of an HCV clone that is infectious in cell culture (termed HCVcc) can di rectly address these shortcomings. The focus of this proposal is to develop the HCVcc system as a more useful tool for drug development. This includes identifying culture methods for increasing HCVcc titer, developing HCVcc genotypes relevant to the domina nt drug development target, and facilitating drug cross-resistance studies by generating mutant infectious HCV viruses that harbor drug resistance mutations reported against experimental anti-HCV compounds presently being developed and evaluated. Results o btained here will not only directly benefit drug development efforts, but will also provide critical information and reagents to a rapidly-developing field of basic research. Infectious HCV for drug discovery.

Principal Investigator:

Amine O. Noueiry
3148128160
NOUEIRY@APATH.COM

Business Contact:

Janet L. Milton
milton@apath.com
Small Business Information at Submission:

APATH, LLC
APATH, LLC 893 N. WARSON RD. SAINT LOUIS, MO 63141

EIN/Tax ID: 431828778
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No